Urgent.News

What's breaking now, across thousands of outlets.

Business

Europe’s moment to lead: Backing research in a global race

Our future depends on choosing to invest in a resilient, competitive, innovative and secure environment in which society can thrive. Our human capital is the foundation of that success, the economic driver of innovation and productivity. Like any source of growth, it requires investment.

Europe’s moment to lead: Backing research in a global race

Europe is facing an aging population and increasing rates of chronic diseases, with more than half of adults now overweight and one in six obese. In addition, Europe is confronted with new health threats, such as malicious use of artificial intelligence, climate-related health issues and drug-resistant superbugs. European teachers, biologists, nurses and manufacturers have contributed to developing innovations that protect and improve the well-being of their populations.

Investing in health research and innovation should not be seen as a discretionary cost, but rather as an economic driver for Europe's future. Health research and innovation are the key to sustainable growth and a pillar of the new global health architecture. The benefits of investment in global health research are evident, as a tuberculosis vaccine has been used for over 40 years to treat bladder cancer and a malaria vaccine technology now helps protect against shingles. mRNA research developed over decades enabled Europe's fastest-ever vaccine response to Covid-19.

Public budgets are under pressure, but the achievements show the potential of investment in global health research. Europe's involvement in global networks of research and innovation is a strategic imperative to enhance health, security, resilience and economic competitiveness. By working together and funding a shared agenda, Europe can maximize the impact of its investments and secure its health, growth and wealth.

Europe’s Health Dividend is a concept funded by the Gates Foundation and Coefficient Giving, highlighting the importance of health research and innovation for Europe's future.

Written by urgent.news from Politico EU's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at politico.eu →

More in Business

Greycoat Research Announces Publication of 3,006-Cat Kidney Data Study

Greycoat Research, a company specializing in feline kidney care, announced on Nov. 16 that a study conducted with researchers in South Korea and Japan, analyzing blood test data from 3,006 cats, was…

  • Greycoat Research published 3,006-cat kidney data study on October 22, 2026
  • Study categorized creatinine levels into seven ranges, analyzed blood test results
  • Researchers found kidney markers and other health indicators don't always align

Samsung, SK hynix Account for 27% of Korea’s Margin Debt

More than a quarter of the margin debt in South Korea’s stock market — money borrowed from brokerages to buy shares — is concentrated in just two stocks: Samsung Electronics and SK hynix.

  • Samsung Electronics and SK hynix hold 27.2% of Korea’s margin debt, totaling 25.60 trillion won.
  • Margin debt concentration surged to 33.6% in August, up from 20% by May.

More from Monday 16 November →